Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type KRAS, Wild type NRAS status confers therapeutic sensitivity to Fluorouracil, Irinotecan, Panitumumab in patients with Colorectal Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved panitumumab 6mg/kg in combination with FOLFIRI (14 day) for reimbursement as a treatment option for the second line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) who have received first-line fluoropyrimidine–based chemotherapy (excluding irinotecan). The European Medicine Agency's product information for Vectibix (panitumumab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.
This statement is based on a regulatory approval from the Health Service Executive:
Second line treatment of adult patients with wild-type RAS mCRC who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).